Company Description
COSCIENS Biopharma Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally.
Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism.
The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024.
COSCIENS Biopharma Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1990 |
| IPO Date | Jul 18, 1996 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Gilles Gagnon |
Contact Details
Address: 222 Bay Street, Suite 3000 Toronto, ON M5K 1E7 Canada | |
| Website | cosciensbio.com |
Stock Details
| Ticker Symbol | CSCI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001113423 |
| CUSIP Number | 22112H101 |
| ISIN Number | CA22112H1010 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Gilles R. Gagnon ICD.D, M.B.A., M.Sc. | President, Chief Executive Officer and Director |
| Giuliano La Fratta | Senior Vice President of Finance and Chief Financial Officer |
| Dr. Michael Teifel Ph.D. | Senior Vice President of Non-Clinical Development and Chief Scientific Officer |
| Dr. Nicola Ammer M.D. | Chief Medical Officer and Senior Vice President of Clinical Development |
| Dr. Matthias Gerlach | Senior Vice President Manufacturing and Supply Chain and Head of Production |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 20, 2024 | SCHEDULE 13D/A | Filing |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Nov 12, 2024 | 6-K | Report of foreign issuer |
| Oct 8, 2024 | 6-K | Report of foreign issuer |
| Oct 1, 2024 | 6-K | Report of foreign issuer |
| Sep 23, 2024 | 6-K | Report of foreign issuer |
| Sep 6, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Aug 27, 2024 | 6-K | Report of foreign issuer |
| Aug 13, 2024 | 6-K | Report of foreign issuer |
| Aug 13, 2024 | 6-K | Report of foreign issuer |